Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors.
Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to Gilead, she spent 18 years at Amgen Inc. in a number of leadership roles in the U.S. and internationally, concluding her time there as Senior Vice President and General Manager, with strategic oversight of Amgen’s U.S. commercial operations.
During her career, Ms. Hamill has worked across a vast array of therapeutic areas, including inflammation, oncology, pain, virology and cardiovascular disease. She is a member of the boards of directors of BB Biotech, AnaptysBio, Inc., Pardes Biosciences, Y-mAbs Therapeutics, Inc., and Unchained Labs, a private company of Carlyle Group. Ms. Hamill also served on the board of director at Acceleron Pharmaceuticals, Inc. before it was acquired by Merck in 2021.
“Laura is joining our board at a particularly opportune time, as Scilex is advancing its clinical development and registration plans for SP-102 (SEMDEXATM) for sciatica pain in an effort to expand its future global commercial footprint. Her breadth of therapeutic-area expertise and lengthy track record of successful global product launches will make her an extremely valuable addition to the organization,” said Henry Ji, Ph.D., Executive Chairman of Scilex Holding and Chair and CEO of Sorrento Therapeutics, Inc.
“I am delighted to join the Board of Scilex. The company’s first commercial product, ZTlido is in the midst of a highly successful growth curve and I’m extremely excited to now be involved as its late-stage clinical and commercial development plans come together for a potential first to market entry into the sciatica and chronic low back pain opportunity. I look forward to helping the company grow its impressive non-opioid pain footprint and help it establish a strong growth trajectory,” said Ms. Hamill.
“We are very pleased to welcome Laura Hamill, a seasoned and highly-regarded leader in our industry as a new independent director to the Scilex Holding board. She is joining at an exciting time as we continue to fulfill our vision to be the leading pain management company delivering novel opioid sparing and non-addictive treatments for safe and durable relief of multiple acute and chronic pain conditions. The addition of Laura complements the skill and experience of our board, and we are confident she will provide very valuable perspectives as we enhance value to our stockholders. We look forward to her contributions,” said Jaisim Shah, President and CEO of Scilex Holding.